Turkish Journal of Nephrology
Original Article

The Association of FGF-23, IL-1 and KIM-1 with Progression and Mortality Rates of Chronic Kidney Disease

1.

Eyüp State Hospital, Department of Internal Medicine, Istanbul, Turkey

2.

Acıbadem Bakırköy Hospital, Department of Nephrology and Internal Medicine, Istanbul, Turkey

3.

Bağcılar Education and Research Hospital, Department of Internal Medicine, Istanbul, Turkey

4.

Bağcılar Education and Research Hospital, Department of Physical Therapy and Rehabilitation, Istanbul, Turkey

5.

Çerkeş State Hospital, Department of Internal Medicine, Çankırı, Turkey

6.

Bağcılar Education and Research Hospital, Department of Biochemistry, Istanbul, Turkey

Turkish J Nephrol 2018; 27: 229-235
DOI: 10.5262/tndt.2018.2972
Read: 474 Downloads: 385 Published: 29 January 2019

OBJECTIVE: We aimed to evaluate the relation of serum Fibroblast Growth Factor 23 (FGF-23),
Interleukin 1 beta (IL-1 beta) and Kidney Injury Molecule 1 (KIM-1) levels with progression and
mortality rates of patients with CKD at the predialysis stage.
MATERIAL and METHODS: A total of 147 patients with CKD who presented to the Internal
Medicine Department of Bagcilar Training and Research Hospital between January and May 2012 were
enrolled into the study. Hemogram analysis, biochemical parameters and serum FGF-23, IL-1 beta and
KIM-1 levels were examined at initial evaluation and at the 48th month of follow-up.
RESULTS: Diabetes mellitus (DM) and hypertension (HT) were major causes of CKD. During the
48-month follow-up period, 51 patients (34.6%) died. A statistically significant relationship was
observed between mortality rates and stage of disease, age, high levels of serum C-reactive protein
(CRP) and ferritin and decreased serum albumin levels; however, the effects of gender and the presence
of DM on mortality were statistically nonsignificant. Relationship of serum FGF-23, IL-1 beta and
KIM-1 with magnesium as well as serum FGF-23 and IL-1 beta with uric acid and IL-1 beta with CRP
were statistically significant.
CONCLUSION: Both initial serum levels and variations of FGF-23, IL-1 beta and KIM-1 had a
nonsignificant impact on mortality of CKD patients during the 48-month follow-up period. Further
studies with a higher number of participants and longer duration of follow-up are required to determine
predictors of prognosis and mortality in patients with CKD.

Files
EISSN 2667-4440